Inclusion criteria

First research question

To determine the effect of CGM on glycaemic control, pregnancy outcomes and participant-reported outcomes compared to SMBG.

Randomized trials

• Women with GDM (diagnosed early and/or later in pregnancy)
• Randomized to treatment with CGM (intervention group, either continuous or intermittent use) and a control group (standard of care) using SMBG
• Follow-up until the end of pregnancy or beyond

Second research question

To determine association between CGM metrics and pregnancy outcomes, and to inform CGM targets.

Randomized trials

• Women with GDM (diagnosed early and/or later in pregnancy)
• Randomized to treatment with CGM (intervention group, either continuous or intermittent use) and a control group (standard of care) using SMBG
• Follow-up until the end of pregnancy or beyond

Cohort studies

• Women with GDM (diagnosed early and/or later in pregnancy)
• Use of (blinded) CGM
• Non-selected or population-based prospective cohorts
• Follow-up until the end of pregnancy and/or beyond

Third research question

To determine effect of CGM on identification who is at increased risk for glucose intolerance postpartum.

Randomized trials

• Women with GDM (diagnosed early and/or later in pregnancy)
• Randomized to treatment with CGM (intervention group, either continuous or intermittent use) and a control group (standard of care) using SMBG
• Follow-up until at least three months postpartum or beyond

Cohort studies

• Women with GDM (diagnosed early and/or later in pregnancy)
• Use of (blinded) CGM
• Non-selected or population-based prospective cohorts
• Follow-up until at least three months postpartum or beyond

Fourth research question

To determine raw CGM data across diverse pregnancy cohorts, on individual person level, to characterise dynamic glycaemic patterns throughout gestation, using machine-learning techniques, and to identify novel CGM-derived metrics and data-driven glycaemic phenotypes associated with adverse pregnancy outcomes.

Randomized trials

• Women with GDM (diagnosed early and/or later in pregnancy)
• Randomized to treatment with CGM (intervention group, either continuous or intermittent use) and a control group (standard of care) using SMBG
• Follow-up until at least three months postpartum or beyond

Cohort studies

• Women with GDM (diagnosed early and/or later in pregnancy)
• Use of (blinded) CGM
• Non-selected or population-based prospective cohorts
• Follow-up until at least three months postpartum or beyond

---

If you wish to participate or require more information, please contact us via the contact form or email [enable javascript to view]

Correspondence to: [enable javascript to view] or [enable javascript to view], ORCID: 0000-0002-3325-0263
Department of Endocrinology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
[enable javascript to view], +32 16 34 06 14